Clin Osteol 2025; 30(1): 30-34

Selected stories from osteonephrology -⁠ an introductionMain theme

Sulková Dusilová Sylvie1, Pavlíková Ladislava2, Pokorná Anita1, Jiráčková Jana2, Hudík Filip1, Malá Alena1, Bílková Lenka2, Matysková Michaela1, Hyšpler Radomír2, Šafránek Roman1, Palička Vladimír2
1 Nefrologická klinika, FN a LF UK v Hradci Králové
2 Osteocentrum, Ustav klinické biochemie a diagnostiky, FN a LF UK v Hradci Králové

Vybrané příběhy z osteonefrologie -⁠ úvod do problematiky
So called osteonephrology deals with the interface between metabolic and other consequences of complex bone and cardiovascular disease in renal disease and also with non-renal metabolic osteopathies in kidney patients.
The article focuses on problems associated with biologic therapy of osteoporosis in patients with chronic kidney disease, including dialysis as well as kidney transplantation. The attention is paid not only to benefit of this therapy, but also on its possible risk, showing the importance of carefull monitoring in hands of nephrologists.

Keywords: metabolic bone disease in nephrology, osteoporosis, denosumab, hypocalcaemia, hyper-parathyresis, safety drug monitoring

Published: March 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dusilová Sylvie S, Pavlíková L, Pokorná A, Jiráčková J, Hudík F, Malá A, et al.. Selected stories from osteonephrology -⁠ an introduction. Clinical Osteology. 2025;30(1):30-34.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. 1. Abduelkarem AR, Guella A, Hamrouni AM, et al. Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review. Risk Manag Healthc Policy. 2023 Sep 11;16 : 1809-1813.
    2. 2. Amann K, Gross ML, London GM, et al. Hyperphosphataemia-a silent killer of patients with renal failure? Nephrol Dial Transplant. 1999 Sep;14(9):2085-7.
    3. 3. Bhanot RD, Kaur J, Bhat Z. Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature. Case Rep Nephrol. 2019 Mar 21;2019 : 3027419.
    4. 4. Bird ST, Smith ER, Gelperin K, et al. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients. JAMA. 2024 Feb 13;331(6):491-499.
    5. 5. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012. Jul;27(7):1471-9.
    6. 6. Brunerova L, Palicka V, Sulkova SD. Commentary of management of osteoporosis in advanced CKD: Common view of a nephrologist and a bone specialist. Endocr Pract. 2019 Feb;25(2):193-196.
    7. 7. Brunova J, Kratochvilova S, Stepankova J. Osteoporosis Therapy With Denosumab in Organ Transplant Recipients. Front Endocrinol (Lausanne). 2018 Apr 17;9 : 162.
    8. 8. Dusilova Sulkova S, Horacek J, Safranek R, et al. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature. Acta Medica (Hradec Kralove). 2014;57(1):30-3.
    9. 9. Gopaul A, Kanagalingam T, Thain J, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Arch Osteoporos. 2021 Jul 28;16(1):116.
    10. 10. Hu L, Napoletano A, Provenzano M, et al. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Int J Mol Sci. 2022 Oct 13;23(20):12223.
    11. 11. Hsu CY, Chen LR, Chen KH. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. Int J Mol Sci. 2020 Sep 18;21(18):6846.
    12. 12. Iseri K, Mizobuchi M, Winzenrieth R, et al. Long-Term Effect of Denosumab on Bone Disease in Patients with CKD. Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1195-1203.
    13. 13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. Go to original source...
    14. 14. Khairallah P, Nickolas TL. Management of Osteoporosis in CKD. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):962-969.
    15. 15. Kobayashi A, Yaginuma T, Kato K, et al. Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLoS One. 2024 Aug 29;19(8):e0309657.
    16. 16. Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis. 2014 Aug;64(2):290-304.
    17. 17. Moe S, Drüeke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun;69(11):1945-53.
    18. 18. Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007 Jan;14(1):3-12.
    19. 19. Naylor KL, Prior J, Garg A, et al. Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function. Clin J Am Soc Nephrol 2016; 11(11):2032-2040.
    20. 20. Nickolas TL. Treating Osteoporosis with Denosumab in Patients on Hemodialysis: The Good, the Bad, and the Ugly. Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1116-1118.
    21. 21. Palička V, Dusilová Sulková S, Brunerová L. Pracovní návrh doporučených postupů pro diagnostiku a léčbu kostních poruch při CKD MBD se specifickým zaměřením na nálezy nízkého obsahu kostního minerálu při vyšetření DXA. Clin Osteol. 2019; 24(4):169-177.
    22. 22. Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021.
    23. 23. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005 Feb;288(2):F253-64.
    24. 24. Torres PAU, Cohen-Solal M. Evaluation of fracture risk in chronic kidney disease. J Nephrol. 2017 Oct;30(5):653-661.
    25. 25. Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb. 2023 Aug 1;30(8):835-850.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.